HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031, driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment. The market is projected to grow at a CAGR of 1% during the forecast period.

HUMIRA (Adalimumab) Drug Market: Introduction

The global HUMIRA (Adalimumab) drug market is a rapidly growing market that provides treatment for various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by suppressing the immune system and reducing inflammation. It is a widely used drug and is considered as a first-line treatment option for many autoimmune diseases. The increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment are the key drivers of the market.

The publisher has released a comprehensive report on the global HUMIRA (Adalimumab) drug market, which provides an in-depth analysis of the market and its segments. HUMIRA is a widely used drug for the treatment of various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The report covers the market for HUMIRA and provides a detailed analysis of the market size, growth, and trends. The market is highly competitive with several key players involved in the market, focusing on developing new drugs and therapies to strengthen their position in the market.

HUMIRA (Adalimumab) Drug Market- Application and Usage

The global HUMIRA (Adalimumab) drug market is used for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by targeting and reducing the activity of a specific protein called tumor necrosis factor-alpha (TNF-alpha) that is involved in causing inflammation in the body. The drug is administered subcutaneously or intravenously, depending on the condition being treated.

Rheumatoid arthritis is one of the primary applications of HUMIRA, and it is widely used as a first-line treatment option for this condition. It is also used for the treatment of psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin. HUMIRA can provide relief from the symptoms of psoriasis by reducing inflammation in the skin.

In addition to rheumatoid arthritis and psoriasis, HUMIRA is also used for the treatment of Crohn's disease and ulcerative colitis. These are chronic inflammatory bowel diseases that affect the digestive system. HUMIRA can help reduce inflammation in the digestive tract and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.

HUMIRA (ADALIMUMAB) Drug Market Segmentations

The market can be categorised into indication, type, dosage strength, drug type, distribution channel, and route of administration.

Market Breakup by Indication

• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Chronic Plaque Psoriasis
• Crohn’s Disease
• Ulcerative Colitis
• Psoriatic Arthritis
• Others

Market Breakup by Type

• Biologics
• Biosimilars
• Adalimumab-ATTO
• Adalimumab-BWWD
• Adalimumab-ADBM
• Adalimumab-ADAZ
• Adalimumab-FKJP
• Adalimumab-AFZB
• Others

Market Breakup by Dosage Strength

• 40MG/0.4ML
• 80MG/0.8ML
• 20MG/0.4ML
• 10MG/0.1ML
• Others

Market Breakup by Drug Type

• Branded
• Generics
• Amjevita
• Hyrimoz
• Hulio
• Others

Market Breakup by Distribution Channels

• Hospital Based Pharmacies
• Online Pharmacies
• Retail Pharmacies

Market Breakup by Route of Administration

• Parenteral
• Oral
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

HUMIRA (Adalimumab) drug Market Scenario

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031. The market is driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment.

North America dominates the HUMIRA drug market, followed by Europe and the Asia Pacific region. The high prevalence of autoimmune diseases and the availability of advanced healthcare infrastructure are driving the growth of the market in North America. Europe is also a significant market for HUMIRA, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

In addition, the COVID-19 pandemic has also affected the HUMIRA drug market, with disruptions in supply chain and manufacturing activities. However, the market is expected to recover in the post-pandemic period, driven by the increasing demand for effective treatments for autoimmune diseases.

Overall, the global HUMIRA (Adalimumab) drug market is expected to continue its growth trajectory during the forecast period, offering numerous opportunities for key players and investors in the industry.

Key Players in the Global HUMIRA (Adalimumab) drug Market

The report gives an in-depth analysis of the key players involved in the HUMIRA (Adalimumab) drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• AbbVie Inc
• Amgen Inc
• Fresenius Kabi AG
• Celltrion Healthcare Co Ltd
• Alvotech Ehf
• Bio-Thera Solutions Ltd
• Zydus Lifesciences Limited
• Hetero Healthcare Ltd
• Innovent Biologics, Inc
• Novartis International AG
• Reliance Life Sciences Pvt. Ltd
• Samsung C&T Corporation
• Terumo Corp
• Torrent Pharmaceuticals Ltd